晚期卵巢癌接受新辅助化疗患者的生存结局:新辅助化疗的指征是否重要?
该研究纳入2015年1月至2022年12月初诊晚期上皮性卵巢癌并接受新辅助化疗的874例患者,按新辅助化疗指征分组,评估指征与生存结局的关联。结果显示Aletti标准、合并症和静脉血栓栓塞组较少接受间歇性减瘤术,其总生存期较仅病灶范围组更短,但多变量分析控制间歇性减瘤术后组间生存无差异。
要点
- 新辅助化疗指征为Aletti标准、合并症或静脉血栓栓塞的患者较少接受间歇性减瘤术。
- Aletti标准组和合并症组的总生存期较仅病灶范围组更差,可能归因于较低的间歇性减瘤术率。
- 控制是否接受间歇性减瘤术后,各组间生存无差异。
核心结论
- 不可改变的患者因素如Aletti标准、合并症和静脉血栓栓塞与未接受间歇性减瘤术相关。
- Aletti标准组或合并症组患者的总生存期较仅病灶范围组更差,可能归因于较低的间歇性减瘤术率。
研究设计与样本
- 回顾性纳入2015年1月至2022年12月初诊晚期上皮性卵巢癌并接受新辅助化疗的患者,共874例,中位年龄68岁(范围26-97),中位随访17.3个月。
主要发现
- 患者分组:仅病灶范围组705/874(80.7%),Aletti标准组18/874(2.1%),合并症组52/874(5.9%),静脉血栓栓塞组57/874(6.5%),其他患者因素组42/874(4.8%)。
- 620/874例(71%)接受间歇性减瘤术,Aletti标准组接受率最低(4/18[22.2%]),合并症组25/52(48.1%),静脉血栓栓塞组37/57(64.9%)。
- 完全肉眼切除率在新辅助化疗指征间无差异(p=0.51)。
- 中位总生存期:仅病灶范围组38.2个月(95%CI:33.6-44.4),合并症组25.9个月(95%CI:21.6-33.2),静脉血栓栓塞组23.7个月(95%CI:12.8-34.7),Aletti标准组20.9个月(95%CI:6.1-26.5),其他患者因素组31.0个月(95%CI:21.4-64.2)。
- 多变量总生存分析控制是否接受间歇性减瘤术后,组间生存无差异(p=0.13)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association between indication for neoadjuvant chemotherapy (NACT) and outcomes in advanced epithelial ovarian cancer (EOC). METHODS: All patients who presented from January 2015 to December 2022 with newly diagnosed advanced EOC undergoing NACT were included. Patients were grouped by NACT indication: extent of disease only (NACT-EOD), Aletti criteria (NACT-Aletti), venous thromboembolism (NACT-VTE), comorbidity (NACT-comorbidity), or other patient factors (NACT-other). Appropriate statistical analyses were performed. RESULTS: This study included 874 patients, with median age 68 years (range, 26-97) and median follow-up 17.3 months. Patient cohorts were: 705/874 (80.7 %) NACT-EOD, 18/874 (2.1 %) NACT-Aletti, 52/874 (5.9 %) NACT-comorbidity, 57/874 (6.5 %) NACT-VTE, 42/874 (4.8 %) NACT-other. In total, 620/874 patients (71 %) underwent interval debulking surgery (IDS), and rates were lowest for NACT-Aletti (4/18 [22.2 %]), NACT-comorbidities (25/52 [48.1 %]), and NACT-VTE (37/57 [64.9 %]). Complete gross resection rate did not differ by NACT indication (p = 0.51). Median overall survival (OS) by NACT indication was 38.2 months (95 % CI: 33.6-44.4) for NACT-EOD, 25.9 months (95 % CI: 21.6-33.2) for NACT-comorbidity, 23.7 months (95 % CI: 12.8-34.7) for NACT-VTE, 20.9 months (95 % CI: 6.1-26.5) for NACT-Aletti criteria, and 31.0 months (95 % CI: 21.4-64.2) for NACT-other. A multivariate OS analysis controlling for whether a patient underwent IDS showed no difference in survival between groups (p = 0.13). CONCLUSIONS: Non-modifiable patient factors such as Aletti criteria, co-morbidities, and VTE were associated with not undergoing IDS. Patients in NACT-Aletti criteria or NACT-comorbidity had worse OS than NACT-EOD, likely attributable to a lower rate of IDS.
引用
- Andres S, Tannous A, Kahn RM, et al. Survival outcomes in patients receiving neoadjuvant chemotherapy for advanced ovarian cancer: Does the indication for neoadjuvant chemotherapy matter? Gynecol Oncol. 2025. PMID: 41135258. doi:10.1016/j.ygyno.2025.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。